“Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients With Psoriasis Who Had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s431. https://doi.org/10.25251/skin.8.supp.431.